| 7.45 -0.27 (-3.5%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.51 | 1-year : | 10.55 |
| Resists | First : | 8.14 | Second : | 9.03 |
| Pivot price | 7.46 |
|||
| Supports | First : | 6.69 | Second : | 5.57 |
| MAs | MA(5) : | 7.58  |
MA(20) : | 7.43 |
| MA(100) : | 7.74 |
MA(250) : | 6.32 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 58.1 |
D(3) : | 58.7 |
| RSI | RSI(14): 46.5 |
|||
| 52-week | High : | 9.5 | Low : | 3.67 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CCEL ] has closed above bottom band by 47.7%. Bollinger Bands are 46.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 7.54 - 7.58 | 7.58 - 7.61 |
| Low: | 7.31 - 7.35 | 7.35 - 7.39 |
| Close: | 7.39 - 7.45 | 7.45 - 7.51 |
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Tue, 16 Jul 2024
Cryo-Cell International (NYSEAMERICAN:CCEL) Announces Quarterly Earnings Results - American Banking and Market News
Mon, 15 Jul 2024
CCEL Stock Earnings: Cryo-Cell International Beats EPS, Beats Revenue for Q2 2024 - InvestorPlace
Mon, 15 Jul 2024
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2024 Financial Results - StockTitan
Sat, 13 Jul 2024
Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) Short Interest Update - MarketBeat
Sun, 24 Mar 2024
symbol__ Stock Quote Price and Forecast - CNN
Wed, 31 Aug 2022
CCEL Stock Price and Chart — AMEX:CCEL - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Care Facilities
|
|
| Shares Out | 8 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 46.1 (%) |
| Held by Institutions | 10.1 (%) |
| Shares Short | 17 (K) |
| Shares Short P.Month | 18 (K) |
| EPS | 0.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0 |
| Profit Margin | 8 % |
| Operating Margin | 16.3 % |
| Return on Assets (ttm) | 4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 2.5 % |
| Gross Profit (p.s.) | 2.59 |
| Sales Per Share | 3.76 |
| EBITDA (p.s.) | 0.7 |
| Qtrly Earnings Growth | 43.7 % |
| Operating Cash Flow | 8 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | 24.83 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 1.97 |
| Price to Cash Flow | 7.71 |
| Dividend | 0.89 |
| Forward Dividend | 0 |
| Dividend Yield | 12% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|